ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias
ABSTRACTS: 57, 58
Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations. Results from the studies were shared today in oral presentations at the 2023 American Society of Hematology (ASH) Annual Meeting. More information...
MD Anderson and Rigel Pharmaceuticals announce strategic alliance to advance olutasidenib in AML and other cancers
The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development...
MD Anderson, TACC and the Oden Institute announce funding for the next round of collaborative cancer research projects
The University of Texas MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the Texas Advanced...
Allison Institute hosts inaugural scientific symposium
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its inaugural scientific symposium on Nov. 10 at the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park. The event brought together more than 400 leading scientists, including three Nobel laureates, from multiple disciplines to share groundbreaking immunotherapy and immunobiology research.
“Our inaugural symposium is an...
MD Anderson announces Institute for Data Science in Oncology to advance mission to end cancer
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates...
MD Anderson and Jazz Pharmaceuticals announce five-year collaboration to evaluate zanidatamab in HER2-expressing cancers
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration...
Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival...
Alejandro Aballay, Pharm.D., Ph.D., named Dean of MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences
The University of Texas MD Anderson Cancer Center and The University of Texas Health Science Center at Houston today announced Alejandro Aballay...
MD Anderson expands breakthrough research campus with groundbreaking of innovative new facility
The University of Texas MD Anderson Cancer Center today broke ground on a 600,000-square-foot facility intended to anchor the institution’...
Enhanced recovery program successfully reduced opioid use after pancreatic cancer surgery
By improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center successfully reduced inpatient opioid...
MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer
The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company...
University of Texas System Regents announce plans to build UT Medical Center on site of Erwin Center
Today The University of Texas System Board of Regents Chairman Kevin P. Eltife announced plans to launch a monumental healthcare initiative...
MD Anderson ranked #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
MD Anderson and Nexo Therapeutics announce strategic research collaboration to advance new therapies against intractable targets
The University of Texas MD Anderson Cancer Center and Nexo Therapeutics today announced a multi-year strategic collaboration that aligns...
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for multiple myeloma
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe...
New single-cell study provides novel insights into gastric cancer
A new study led by researchers at The University of Texas MD Anderson Cancer Center provides a deeper understanding of the evolution of the...
MD Anderson and Ochsner Health announce partnership to create first fully integrated cancer program in Louisiana
The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner...
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued...
ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
ABSTRACTS: 3121, 4504, LBA4619
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated...
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
ABSTRACT: 4008
HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2...
Allison Institute announces appointment of inaugural members
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the appointment of its first members,...
MD Anderson researchers Helen Piwnica-Worms and Richard Wood elected to National Academy of Sciences
Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the prestigious National Academy of...
MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI
The University of Texas MD Anderson Cancer Center and Generate:Biomedicines today announced a strategic collaboration to jointly discover...
AACR: Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
ABSTRACT: 3431
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations...
MD Anderson applauds NCI’s National Cancer Plan
The University of Texas MD Anderson Cancer Center applauds the National Cancer Institute’s (NCI) National Cancer Plan and its framework...
Kerin Adelson, M.D., named MD Anderson Chief Quality and Value Officer
The University of Texas MD Anderson Cancer Center today announced Kerin Adelson, M.D., as the institution’s chief quality and value officer...
MD Anderson and Xilis announce strategic collaboration to advance novel technology and accelerate therapeutic development
The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere...
MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy
The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company...
MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson...